Formulations:
- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
Indications:
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Other specified gliomas of brain
- Follicular lymphoma
- Malignant trophoblastic neoplasms of placenta
- Diffuse large B-cell lymphoma, not otherwise specified
- Kaposi sarcoma of unspecified primary site
- Rhabdomyosarcoma primary site
- Hodgkin lymphoma
- Burkitt lymphoma including Burkitt leukaemia
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Malignant neoplasms of kidney, except renal pelvis
- Lymphoid leukaemia, not elsewhere classified
- Retinoblastoma
- Langerhans cell histiocytosis
Source: EML workbook import
Product metadata will be available once the catalog entry is complete.
Formulations:
- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
Indications:
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Other specified gliomas of brain
- Follicular lymphoma
- Malignant trophoblastic neoplasms of placenta
- Diffuse large B-cell lymphoma, not otherwise specified
- Kaposi sarcoma of unspecified primary site
- Rhabdomyosarcoma primary site
- Hodgkin lymphoma
- Burkitt lymphoma including Burkitt leukaemia
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Malignant neoplasms of kidney, except renal pelvis
- Lymphoid leukaemia, not elsewhere classified
- Retinoblastoma
- Langerhans cell histiocytosis
Source: EML workbook import